NasdaqGM:ADMS

Stock Analysis Report

Executive Summary

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • Adamas Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Adamas Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.6%

NasdaqGM:ADMS

1.7%

US Biotechs

2.1%

US Market


1 Year Return

-72.2%

NasdaqGM:ADMS

-9.1%

US Biotechs

-0.04%

US Market

ADMS underperformed the Biotechs industry which returned -9.1% over the past year.

ADMS underperformed the Market in United States of America which returned -0% over the past year.


Share holder returns

ADMSIndustryMarket
7 Day-5.6%1.7%2.1%
30 Day0.5%0.7%-3.2%
90 Day21.4%2.4%2.8%
1 Year-72.2%-72.2%-8.3%-9.1%2.2%-0.04%
3 Year-53.8%-53.8%11.9%8.1%41.5%32.3%
5 Year-67.7%-67.7%5.2%0.3%55.0%37.8%

Price Volatility Vs. Market

How volatile is Adamas Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Adamas Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Adamas Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Adamas Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Adamas Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Adamas Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Adamas Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Adamas Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Adamas Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

46.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Adamas Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Adamas Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Adamas Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Adamas Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Adamas Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Adamas Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Adamas Pharmaceuticals performed over the past 5 years?

-46.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Adamas Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Adamas Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Adamas Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Adamas Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Adamas Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Adamas Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

  • Explore strong past performing companies in the Pharmaceuticals & Biotech industry.

Financial Health

How is Adamas Pharmaceuticals's financial position?


Financial Position Analysis

Adamas Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Adamas Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Adamas Pharmaceuticals's level of debt (289.3%) compared to net worth is high (greater than 40%).

Unable to establish if Adamas Pharmaceuticals's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.5x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Adamas Pharmaceuticals has sufficient cash runway for 1.8 years based on current free cash flow.

Adamas Pharmaceuticals has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 30% each year.


Next Steps

Dividend

What is Adamas Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Adamas Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Adamas Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Adamas Pharmaceuticals has not reported any payouts.

Unable to verify if Adamas Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Adamas Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Adamas Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Adamas Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Gregory Went (55yo)

19.6yrs

Tenure

US$3,359,123

Compensation

Dr. Gregory T. Went, Ph.D. is a Co-founder and Chairman of NeuroMolecular. Dr. Went co-founded Tethys Bioscience Inc. in 2002 and served as its Chairman of the Board. Dr. Went co-founded Adamas Pharmaceuti ...


CEO Compensation Analysis

Gregory's remuneration is higher than average for companies of similar size in United States of America.

Gregory's compensation has increased whilst company is loss making.


Management Age and Tenure

2.2yrs

Average Tenure

50yo

Average Age

The tenure for the Adamas Pharmaceuticals management team is about average.


Board Age and Tenure

15.1yrs

Average Tenure

65.5yo

Average Age

The average tenure for the Adamas Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

Adamas Pharmaceuticals individual insiders have only sold shares in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$6,49223 Jul 19
Christopher Prentiss
EntityIndividual
Role
Chief Accounting Officer
Senior VP of Finance & Chief Accounting Officer
Shares1,082
Max PriceUS$6.00
SellUS$5,02921 Jun 19
Jennifer Rhodes
EntityIndividual
Role
Chief Legal Officer
Chief Business Officer
Shares940
Max PriceUS$5.35
SellUS$6,84721 Mar 19
Alfred Merriweather
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares857
Max PriceUS$7.99
SellUS$18,99221 Mar 19
Rajiv Patni
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares2,374
Max PriceUS$8.00
SellUS$9,48021 Mar 19
Christopher Prentiss
EntityIndividual
Role
Chief Accounting Officer
Senior VP of Finance & Chief Accounting Officer
Shares1,185
Max PriceUS$8.00
SellUS$14,31821 Mar 19
Jennifer Rhodes
EntityIndividual
Role
Chief Legal Officer
Chief Business Officer
Shares1,792
Max PriceUS$7.99
SellUS$50,48921 Mar 19
Gregory Went
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares6,319
Max PriceUS$7.99
SellUS$1,71226 Dec 18
Christopher Prentiss
EntityIndividual
Role
Chief Accounting Officer
Senior VP of Finance & Chief Accounting Officer
Shares228
Max PriceUS$7.51
SellUS$3,19621 Dec 18
Jennifer Rhodes
EntityIndividual
Role
Chief Legal Officer
Chief Business Officer
Shares425
Max PriceUS$7.52
BuyUS$49,95608 Nov 18
Gregory Went
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares3,850
Max PriceUS$12.98
SellUS$31,93521 Sep 18
Alfred Merriweather
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,665
Max PriceUS$19.18

Ownership Breakdown


Management Team

  • Alf Merriweather (65yo)

    Chief Financial Officer

    • Tenure: 2.2yrs
    • Compensation: US$1.64m
  • Gregory Went (55yo)

    Co-Founder

    • Tenure: 19.6yrs
    • Compensation: US$3.36m
  • Dean Hart

    Senior Vice President of Sales

    • Tenure: 0.0yrs
  • Melissa Masterson

    Senior Vice President of Commercial Operations & Market Access

    • Tenure: 0.0yrs
  • Rajiv Patni (50yo)

    Chief Medical Officer

    • Tenure: 4.2yrs
    • Compensation: US$1.75m
  • Jennifer Rhodes (49yo)

    Chief Business Officer

    • Tenure: 3.3yrs
    • Compensation: US$1.46m
  • Chris Prentiss (44yo)

    Senior VP of Finance & Chief Accounting Officer

    • Tenure: 1.9yrs
  • Sarah Mathieson

    Head of Corporate Communications & Engagement and VP of Corporate Communications

    • Tenure: 0.5yrs
  • Vijay Shreedhar

    Chief Commercial Officer

    • Tenure: 0.3yrs

Board Members

  • Bill Ericson (60yo)

    Independent Director

    • Tenure: 14.6yrs
    • Compensation: US$222.74k
  • Martha Demski (66yo)

    Independent Director

    • Tenure: 5.4yrs
    • Compensation: US$232.24k
  • David Mahoney (65yo)

    Lead Independent Director

    • Tenure: 0.0yrs
    • Compensation: US$240.61k
  • Gregory Went (55yo)

    Co-Founder

    • Tenure: 19.6yrs
    • Compensation: US$3.36m
  • Ivan Lieberburg (69yo)

    Independent Director

    • Tenure: 15.6yrs
    • Compensation: US$206.99k
  • Jeff Cummings (70yo)

    Scientific & Clinical Advisor

    • Tenure: 0.0yrs
  • Arnold Monto

    Member of Influenza Advisory Board

    • Tenure: 0.0yrs
  • Matthew Stern

    Scientific & Clinical Advisor

    • Tenure: 0.0yrs
  • Martin Farlow

    Member of CNS Advisory Board

    • Tenure: 0.0yrs
  • Alan Perelson

    Member of Influenza Advisory Board

    • Tenure: 0.0yrs

Company Information

Adamas Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Adamas Pharmaceuticals, Inc.
  • Ticker: ADMS
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$168.293m
  • Shares outstanding: 27.77m
  • Website: https://www.adamaspharma.com

Number of Employees


Location

  • Adamas Pharmaceuticals, Inc.
  • 1900 Powell Street
  • Suite 750
  • Emeryville
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADMSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2014
136DB (Deutsche Boerse AG)YesCommon StockDEEURApr 2014

Biography

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended rele ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 00:57
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.